{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T20:13:38Z","timestamp":1792700018810,"version":"4.5.0"},"reference-count":71,"publisher":"Informa UK Limited","issue":"6","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Therapeutic Delivery"],"published-print":{"date-parts":[[2024,6,2]]},"DOI":"10.1080\/20415990.2024.2343646","type":"journal-article","created":{"date-parts":[[2024,5,22]],"date-time":"2024-05-22T08:01:50Z","timestamp":1716364910000},"page":"449-462","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":5,"title":["Fabrication and characterization of apremilast-loaded zinc oxide-mesoporous silica nanoparticles for psoriasis treatment"],"prefix":"10.1080","volume":"15","author":[{"given":"Mrunal","family":"Rahangdale","sequence":"first","affiliation":[{"name":"Faculty of Pharmacy, The Maharaja Sayajirao University of Baroda, Kalabhavan Campus, Vadodara, 390001, Gujarat, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shubham","family":"Solanki","sequence":"additional","affiliation":[{"name":"Faculty of Pharmacy, The Maharaja Sayajirao University of Baroda, Kalabhavan Campus, Vadodara, 390001, Gujarat, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pravin","family":"Patil","sequence":"additional","affiliation":[{"name":"Faculty of Pharmacy, The Maharaja Sayajirao University of Baroda, Kalabhavan Campus, Vadodara, 390001, Gujarat, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dhaval","family":"Bhavsar","sequence":"additional","affiliation":[{"name":"Faculty of Pharmacy, The Maharaja Sayajirao University of Baroda, Kalabhavan Campus, Vadodara, 390001, Gujarat, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7716-2759","authenticated-orcid":false,"given":"Krutika","family":"Sawant","sequence":"additional","affiliation":[{"name":"Faculty of Pharmacy, The Maharaja Sayajirao University of Baroda, Kalabhavan Campus, Vadodara, 390001, Gujarat, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2024,5,22]]},"reference":[{"key":"e_1_3_8_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)61128-3"},{"key":"e_1_3_8_4_1","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.743180"},{"key":"e_1_3_8_5_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m1590"},{"issue":"4","key":"e_1_3_8_6_1","first-page":"278","article-title":"Diagnosis and management of psoriasis","volume":"63","author":"Kim WB","year":"2017","unstructured":"Kim WB, Jerome D, Yeung J. Diagnosis and management of psoriasis. Can Fam Physician. 2017;63(4):278\u2013285.","journal-title":"Can Fam Physician."},{"key":"e_1_3_8_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2009.08.026"},{"key":"e_1_3_8_8_1","doi-asserted-by":"publisher","DOI":"10.2147\/PTT.S375173"},{"issue":"4","key":"e_1_3_8_9_1","first-page":"13","article-title":"Recommendations for initiating systemic therapy in patients with psoriasis","volume":"12","author":"Martin G","year":"2019","unstructured":"Martin G, Young M, Aldredge L. Recommendations for initiating systemic therapy in patients with psoriasis. J Clin Aesthet Dermatol. 2019;12(4):13\u201326.","journal-title":"J Clin Aesthet Dermatol."},{"issue":"8","key":"e_1_3_8_10_1","first-page":"495","article-title":"Apremilast (Otezla): a new oral treatment for adults with psoriasis and psoriatic arthritis","volume":"40","author":"Zerilli T","year":"2015","unstructured":"Zerilli T, Ocheretyaner E. Apremilast (Otezla): a new oral treatment for adults with psoriasis and psoriatic arthritis. PT. 2015;40(8):495\u2013500.","journal-title":"PT."},{"key":"e_1_3_8_11_1","first-page":"105","article-title":"Otezla (Apremilast), an oral PDE-4 inhibitor, receives FDA approval for the treatment of patients with active psoriatic arthritis and plaque psoriasis","volume":"8","author":"Fala L","year":"2015","unstructured":"Fala L. Otezla (Apremilast), an oral PDE-4 inhibitor, receives FDA approval for the treatment of patients with active psoriatic arthritis and plaque psoriasis. Am Health Drug Benefits. 2015;8(Spec Feature):105\u2013110.","journal-title":"Am Health Drug Benefits."},{"key":"e_1_3_8_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jddst.2020.101844"},{"key":"e_1_3_8_13_1","doi-asserted-by":"publisher","DOI":"10.3390\/molecules27103085"},{"key":"e_1_3_8_14_1","doi-asserted-by":"publisher","DOI":"10.2147\/IJN.S195048"},{"key":"e_1_3_8_15_1","unstructured":"Joharapurkar AA Sutariya BK Jain MR Kulkarni SK Hothur KR Sirwani RP. Topical formulation of apremilast. US20190060221."},{"key":"e_1_3_8_16_1","doi-asserted-by":"publisher","DOI":"10.1208\/s12249-017-0776-3"},{"key":"e_1_3_8_17_1","doi-asserted-by":"publisher","DOI":"10.3390\/ph13120484"},{"key":"e_1_3_8_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.colsurfb.2021.111945"},{"key":"e_1_3_8_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jddst.2023.105211"},{"key":"e_1_3_8_20_1","doi-asserted-by":"publisher","DOI":"10.37285\/ijpsn.2021.14.3.8"},{"key":"e_1_3_8_21_1","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics14051011"},{"key":"e_1_3_8_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-030-39246-8_9"},{"key":"e_1_3_8_23_1","doi-asserted-by":"publisher","DOI":"10.3389\/fddev.2022.957732"},{"key":"e_1_3_8_24_1","doi-asserted-by":"publisher","DOI":"10.1080\/03639045.2019.1576722"},{"key":"e_1_3_8_25_1","doi-asserted-by":"publisher","DOI":"10.2174\/2211738506666180523112513"},{"key":"e_1_3_8_26_1","doi-asserted-by":"publisher","DOI":"10.4103\/2230-973X.160844"},{"key":"e_1_3_8_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.micromeso.2018.12.026"},{"key":"e_1_3_8_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2021.121079"},{"key":"e_1_3_8_29_1","doi-asserted-by":"publisher","DOI":"10.1002\/open.202100227"},{"key":"e_1_3_8_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-0960.1997.tb01692.x"},{"key":"e_1_3_8_31_1","doi-asserted-by":"publisher","DOI":"10.2310\/7750.2012.11124"},{"key":"e_1_3_8_32_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12034-014-0709-7"},{"key":"e_1_3_8_33_1","doi-asserted-by":"publisher","DOI":"10.1021\/cm990661z"},{"key":"e_1_3_8_34_1","doi-asserted-by":"publisher","DOI":"10.3390\/nano8050317"},{"key":"e_1_3_8_35_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10853-010-4652-8"},{"key":"e_1_3_8_36_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10971-016-4163-4"},{"key":"e_1_3_8_37_1","doi-asserted-by":"publisher","DOI":"10.1080\/19443994.2015.1014856"},{"key":"e_1_3_8_38_1","first-page":"47","article-title":"Development and validation of a stability-indicating reversed phase HPLC method for determination of apremilast in bulk and pharmaceutical dosage form","volume":"5","author":"Sulthana S","year":"2020","unstructured":"Sulthana S, Kamma H, Sri Sankar R. Development and validation of a stability-indicating reversed phase HPLC method for determination of apremilast in bulk and pharmaceutical dosage form. IJRPB. 2020;5:47\u201353.","journal-title":"IJRPB."},{"key":"e_1_3_8_39_1","doi-asserted-by":"publisher","DOI":"10.1088\/1742-6596\/1912\/1\/012045"},{"issue":"2","key":"e_1_3_8_40_1","first-page":"201","article-title":"Preparation and evaluation of herbal gel formulation","volume":"1","author":"Jamadar MJ","year":"2017","unstructured":"Jamadar MJ, Shaikh RH. Preparation and evaluation of herbal gel formulation. JPRE. 2017;1(2):201\u2013224.","journal-title":"JPRE."},{"key":"e_1_3_8_41_1","doi-asserted-by":"publisher","DOI":"10.3390\/scipharm87040032"},{"key":"e_1_3_8_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejpb.2008.01.013"},{"key":"e_1_3_8_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.micromeso.2011.02.022"},{"key":"e_1_3_8_44_1","doi-asserted-by":"publisher","DOI":"10.3762\/bjnano.9.64"},{"key":"e_1_3_8_45_1","first-page":"71","article-title":"Synthesis and characterization of zinc oxide nanoparticles by using polyol chemistry for their antimicrobial and antibiofilm activity","volume":"17","author":"Pranjali PM","year":"2019","unstructured":"Pranjali PM, Pooja MP, Maruti JD, et al. Synthesis and characterization of zinc oxide nanoparticles by using polyol chemistry for their antimicrobial and antibiofilm activity. Biochem Biophys Rep. 2019;17:71\u201380.","journal-title":"Biochem Biophys Rep."},{"key":"e_1_3_8_46_1","doi-asserted-by":"publisher","DOI":"10.1039\/c3sc50697e"},{"key":"e_1_3_8_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jssc.2012.05.030"},{"key":"e_1_3_8_48_1","doi-asserted-by":"publisher","DOI":"10.1134\/S1061933X13030125"},{"key":"e_1_3_8_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-323-46139-9.00005-0"},{"key":"e_1_3_8_50_1","doi-asserted-by":"publisher","DOI":"10.1515\/rams-2021-0009"},{"issue":"4","key":"e_1_3_8_51_1","first-page":"107","article-title":"Formulation and evaluation of valdecoxib gel for topical administration","volume":"5","author":"Rastogi B","year":"2015","unstructured":"Rastogi B, Chaudhary AJ. Formulation and evaluation of valdecoxib gel for topical administration. JAPER. 2015;5(4):107\u2013110.","journal-title":"JAPER."},{"key":"e_1_3_8_52_1","doi-asserted-by":"publisher","DOI":"10.4103\/0250-474X.57291"},{"key":"e_1_3_8_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0928-0987(01)00095-1"},{"key":"e_1_3_8_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.colsurfb.2019.06.018"},{"key":"e_1_3_8_55_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.apt.2017.02.003"},{"key":"e_1_3_8_56_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2019.104972"},{"key":"e_1_3_8_57_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0137890"},{"key":"e_1_3_8_58_1","first-page":"5","volume-title":"Psoriasis.","author":"Sandra RM","year":"2017","unstructured":"Sandra RM, Juan CCD, Isa\u00ed Mart\u00ednez- T, Sonia MPT, Mario ECD. Psoriatic animal models developed for the study of the disease. In: Anca C, editor. Psoriasis. IntechOpen Rijeka Ch; 2017. p. 5."},{"key":"e_1_3_8_59_1","doi-asserted-by":"publisher","DOI":"10.4103\/0019-5154.113948"},{"key":"e_1_3_8_60_1","doi-asserted-by":"publisher","DOI":"10.3109\/15569527.2014.963598"},{"key":"e_1_3_8_61_1","doi-asserted-by":"publisher","DOI":"10.1208\/s12249-014-0253-1"},{"key":"e_1_3_8_62_1","doi-asserted-by":"publisher","DOI":"10.4103\/idoj.IDOJ_437_18"},{"key":"e_1_3_8_63_1","doi-asserted-by":"publisher","DOI":"10.2147\/NSA.S19419"},{"issue":"4","key":"e_1_3_8_64_1","first-page":"187","article-title":"Treatment of localized psoriasis with a topical formulation of zinc pyrithione","volume":"20","author":"Sadeghian G","year":"2011","unstructured":"Sadeghian G, Ziaei H, Nilforoushzadeh MA. Treatment of localized psoriasis with a topical formulation of zinc pyrithione. Acta Dermatovenerol Alp Pannonica Adriat. 2011;20(4):187\u2013190.","journal-title":"Acta Dermatovenerol Alp Pannonica Adriat."},{"key":"e_1_3_8_65_1","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/709152"},{"issue":"1","key":"e_1_3_8_66_1","first-page":"27","article-title":"Preparation and characterization of rifampin loaded mesoporous silica nanoparticles as a potential system for pulmonary drug delivery","volume":"14","author":"Mohseni M","year":"2015","unstructured":"Mohseni M, Gilani K, Mortazavi SA. Preparation and characterization of rifampin loaded mesoporous silica nanoparticles as a potential system for pulmonary drug delivery. Iran J Pharm Res. 2015;14(1):27\u201334.","journal-title":"Iran J Pharm Res."},{"key":"e_1_3_8_67_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcis.2017.07.027"},{"key":"e_1_3_8_68_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2010.11.015"},{"key":"e_1_3_8_69_1","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics10020057"},{"key":"e_1_3_8_70_1","doi-asserted-by":"publisher","DOI":"10.1186\/s11671-017-1853-y"},{"key":"e_1_3_8_71_1","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics10030118"},{"key":"e_1_3_8_72_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2012.04.051"},{"key":"e_1_3_8_73_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms232415980"}],"container-title":["Therapeutic Delivery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/20415990.2024.2343646","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,24]],"date-time":"2024-09-24T17:49:19Z","timestamp":1727200159000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/20415990.2024.2343646"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,22]]},"references-count":71,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6,2]]}},"alternative-id":["10.1080\/20415990.2024.2343646"],"URL":"https:\/\/doi.org\/10.1080\/20415990.2024.2343646","relation":{},"ISSN":["2041-5990","2041-6008"],"issn-type":[{"value":"2041-5990","type":"print"},{"value":"2041-6008","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,22]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=itde20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=itde20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2023-10-31","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-04-12","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-05-22","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}